Danaher, Merck KGaA and General Electric are dominating the Global Oligonucleotides Synthesis Market in 2018

Global Oligonucleotides Synthesis Market is expected to reach USD 3,513.64 million by 2026 from USD 1,744.36 million in 2018 at a substantial CAGR of 9.3% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below:

Access Full Report at https://databridgemarketresearch.com/reports/global-oligonucleotide-synthesis-market

Global oligonucleotides synthesis market is an upcoming market which includes key players and local players. The market is growing owing to the favourable market scenario. The market has a prominent growth in upcoming years due to Increasing usage of synthesized oligos in molecular diagnostics and clinical applications and increasing government investments, R&D expenditure in pharmaceutical and biotechnology companies. The market has witnessed developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of oligonucleotides synthesis market.  For instance, In June 2019, GENERAL ELECTRIC and Nyansa had announced partnership for distribution of Nyansa Voyance AIOps for patients. With this, the companies have GE CARESCAPE Network portfolio. This will help to overcome the challenges in transformation of digital health care.

Danaher dominated the global oligonucleotides synthesis market and accounts for the highest market share in 2018. The other key players in the market are Merck KGaA, GENERAL ELECTRIC, Agilent Technologies, Inc., Atdbio Ltd., LGC Limited, Bio-Synthesis Inc., Eurofins Genomics, Kaneka Eurogentec S.A., , Genscript, AJINOMOTO CO.,INC (Genedesign, Inc.), Lgc Biosearch Technologies, Nitto Denko, Thermo Fisher Scientific, Trilink Biotechnologies, Llc, Biolytic Lab Performance Inc., Polygen Gmbh, Quintara Biosciences, Bio Basic Inc., Danaher (Integrated Dna Technologies, Inc.), and Twist Bioscience among others.


Danaher is headquartered in Pennsylvania, U.S., was founded in 1969. The company is engaged in helping customers achieve high standards by innovating forward-looking technologies to solve customers’ most complex challenges. The companies has four business segments which are Life Science, Diagnostics, Dental, Environmental & Applied Solutions in which Diagnostics is market focused segment. Product categories of the company include DNA & RNA, CRISPR genome editing, Next generation sequencing, Genes & gene fragments qPCR & PCR, Functional genomics, Reagents and kits, GMP, OEM & integrations, Optional services in which DNA & RNA is market focused category. The company has Approx. 71,000 employees as of 31st, December 2018.

  • In September 2018, Danaher Corporation held conference in New York City. With this conference, there will be increased awareness and promotion of products which helps to solve some problems related diseases and improving health of customers across the world.

The company has global presence in China, Europe and India. It sells its products through following subsidiaries ALLTEC/FOBA (Germany), Beckman Coulter (U.S.), Implant Direct (U.S.), KaVo Kerr (U.S.), Integrated DNA Technologies, Inc. (U.S.) and others.

Merck KGaA

Merck KGaA, Inc. is headquartered in Darmstadt, Germany was founded in 1891. The company is engaged in providing new ways to treat and protect the people and animals from illness around the world. The company has three business segments which are pharmaceuticals, animal health and others in which pharmaceuticals is market focused segment. The product categories of the company include Analytical/Chromatography, Life Science, Oligos & QPCR Probes, Chemistry, Materials Science, Labware and Services in which Oligos & QPCR Probes is market focused category. The company has Approx. 69,000 employees as of 31st December, 2018.

  • In November 2017, Merck KGaA, declared that its Massachusetts based business sectors MilliporeSigma and EMD Serono, included their name to the Boston Globe's annual "Top Places to Work" list.

The company has global presence in North America, South America, Europe, Asia-Pacific, Middle East & Africa. It sells its products through following subsidiaries Organon International (Netherlands), Merck Sharp & Dohme ltd (U.K), Aptus Health, Inc. (U.S.), Idenix Pharmaceuticals, Inc.(U.S.), Merck Banyu Co Ltd ( Japan).


GENERAL ELECTRIC is headquartered in Massachusetts, U.S., was established in 1892. The company is combining world-class engineering with software, manufacturing, materials science and data analytics to deliver high value to customers. The company has eight business segments which are Power, Renewable Energy, Aviation, Oil & Gas, Healthcare, Transportation, Lightings, Capital in which Healthcare is market focused segment. The business categories of the company include GE Additive, GE Aviation, GE Capital, GE Digital, GE Healthcare, GE Lighting, GE Power, GE Renewable Energy, GE Research in which GE Healthcare is market focused category. The company has Approx. 283,000 employees.

  • In May 2019, GENERAL ELECTRIC and Indi Molecular, Inc, together gives diagnostics tool for clinical management of patients having immunotherapy. With this there is development of non-invasive immune cell-targeted Positron-Emission Tomography (PET) tracing agents. These agents are used to detect molecular markers of cytotoxic T-cells and help to monitor the immunotherapy.

The company has global presence in Europe, America, Asia-Pacific, Middle East and Africa. It sells its products through following subsidiaries GE Capital or Financial Services (U.S.), GE Healthcare (U.S.), General Electric Capital Corporation or GECC (U.S.), GE Industrial (U.S.), GE Capital Global Holdings, LLC (U.S.), Baker Hughes (U.S.) and others.